Delcath Systems, Inc. (NASDAQ:DCTH) Short Interest Update

Delcath Systems, Inc. (NASDAQ:DCTH) saw a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 1,350,000 shares, a decline of 10.6% from the November 30th total of 1,510,000 shares. Based on an average daily volume of 371,800 shares, the short-interest ratio is presently 3.6 days.

Delcath Systems Trading Up 1.3 %

NASDAQ:DCTH traded up $0.15 on Wednesday, hitting $12.04. 214,022 shares of the company’s stock traded hands, compared to its average volume of 286,478. The company has a market cap of $384.97 million, a PE ratio of -8.92 and a beta of 0.85. Delcath Systems has a 1 year low of $3.70 and a 1 year high of $13.30. The firm has a 50-day moving average price of $11.00 and a 200-day moving average price of $9.53.

Analysts Set New Price Targets

A number of research firms recently weighed in on DCTH. Stephens reiterated a “buy” rating on shares of Delcath Systems in a research report on Friday, October 18th. Canaccord Genuity Group reiterated a “buy” rating and issued a $21.00 target price on shares of Delcath Systems in a report on Friday, October 18th. StockNews.com raised shares of Delcath Systems from a “sell” rating to a “hold” rating in a research report on Friday, October 25th. Finally, HC Wainwright restated a “buy” rating and issued a $22.00 price target on shares of Delcath Systems in a research report on Monday, November 11th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Delcath Systems currently has a consensus rating of “Moderate Buy” and an average price target of $21.50.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Polar Asset Management Partners Inc. acquired a new stake in shares of Delcath Systems during the 3rd quarter valued at $1,594,000. Shellback Capital LP acquired a new stake in Delcath Systems during the second quarter valued at $1,353,000. Principal Financial Group Inc. purchased a new position in Delcath Systems in the third quarter valued at about $808,000. Renaissance Technologies LLC acquired a new position in Delcath Systems in the 2nd quarter worth about $694,000. Finally, Cubist Systematic Strategies LLC bought a new position in Delcath Systems during the second quarter valued at approximately $370,000. 61.12% of the stock is owned by hedge funds and other institutional investors.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.